Prostate cancer: Focal One®, a revolutionary treatment
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57
 
Prostate cancer: Focal One®, a revolutionary treatment

Focal One® is a computer-controlled medical device for the treatment of localised prostate cancer by focused ultrasound (HIFU = High Intensity Focused Ultrasound). The energy is delivered via an endorectal probe. The ultrasound waves travel through the rectal wall and are focused on a part of the prostate. This focusing produces intense heat, resulting in tissue destruction within the target area. The treatment lasts between 30 minutes and 2 hours and can be performed under loco-regional anaesthesia.

Focal One® is a non-invasive treatment option that allows for a precise, local treatment in one session, that can be repeated if necessary, with a short hospital stay and few side effects. In the event of incomplete results, the choice of therapeutic options is wide and includes retreatment with Focal One®.

Focal One® may be indicated as:

  • a first line option for patients with localised cancer, stage T1-T2 (Gleason 6 or 7, PSA less than 15), according to their age and general condition.
  • a salvage therapy option for patients with local recurrence of prostate cancer initially treated by radiotherapy.

HIFU for prostate cancer

HIFU uses a high intensity convergent ultrasound beam generated by piezoelectric transducers. This focusing of ultrasound waves into one point greatly increases the temperature around the focal point, thus resulting in tumour destruction i.e. pathological biological tissue.

The application of HIFU for prostate cancer treatment involves focusing high intensity focused ultrasound to destroy, by heat, prostatic tissue affected by cancer, without damaging surrounding tissue. This technique is non-invasive because it avoids incision, allows loco-regional anaesthesia and limits the characteristic complications of prostate cancer treatment (incontinence or impotence).

Clinical results

In 2013 and 2014, two prospective cohort studies demonstrated the long-term (10 years) results of whole gland HIFU as a first-line option and have validated its effectiveness: according to the cancer risk, the specific survival rate at 10 years is between 92 and 99%; survival rate without metastases at 10 years is between 86% and 100%. These results, which are completely comparable to the best radical surgery results, demonstrate that HIFU is an effective first-line treatment option for localised prostate cancer.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
nutrition
oncology
prevention
dermatology
cancer
Anti-aging
age management
detoxification
skin
diagnosis
heavy metal
cardiology
immunology
liver detox
oncology treatment
DNA
pain
Genetics
stem cells
allergy
Fertility
weight management
infertility
weight loss
liver
cosmetology
gastroenterology
Sleep
gynecology
Examination partner centres
rehabilitation
chelation
obstetrics
pregnancy
headache
check-up
anti-aging
candida
radiology
immune system
neurology
urology
arsenic
breast cancer
immunotherapy
probiotics
NAD+
mesotherapy
Apnea
tinnitus
Дерматология
joints
Hepatitis C
heart MRI
covid19
Blood pressure
skincare
ulcer
research
abdominal pain
sugar
menopause
migraine
beau-rivage
hyaluronic acid
Allergology
pancreas
gastritis
flu vaccine
gastroscopy
rhesus factor
preventiion
brain surgery awake
andropause
sexuality
obstertics
PRP
light therapy
nutrigenomics
excimer laser
psoriasis
regeneration
telomere
mastectomy
narcosis
hand
shoulder
intestinal flora
depression
second opinion
iron
Omega-3
R-loops
cellmen
mammography
cellcosmet
herniated disc
magnesium
flu
reflexology
vitamin K
exercise
beauty
sports
cholesterol
Treatment programs
stress
knee
hip
vitamin b12
food
mercury
water
back pain
erectile dysfunction
food intolerances
diabetes
acne
endometriosis
LED therapy
biopsy
oral checkup
liquid biopsy
blood test
reconstruction
acnea
digestion
migraines
chronic headaches
oncoloy
diet
dermatitis
endocrinology
rheumatology
pomegranate
orthopedics
colonoscopy
propofole
cellulite
proctology
pneumology
general surgery
hormones
nephrology
kidney
lungs
plastic surgery
ophthalmology